These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

217 related items for PubMed ID: 15337125

  • 1. The pathogenesis of primary progressive multiple sclerosis: antibody-mediated attack and no repair?
    Pender MP.
    J Clin Neurosci; 2004 Sep; 11(7):689-92. PubMed ID: 15337125
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. The challenge of multiple sclerosis: how do we cure a chronic heterogeneous disease?
    Weiner HL.
    Ann Neurol; 2009 Mar; 65(3):239-48. PubMed ID: 19334069
    [Abstract] [Full Text] [Related]

  • 4. Natural history of multiple sclerosis: a unifying concept.
    Confavreux C, Vukusic S.
    Brain; 2006 Mar; 129(Pt 3):606-16. PubMed ID: 16415308
    [Abstract] [Full Text] [Related]

  • 5. Interferon-beta regulates cytokines and BDNF: greater effect in relapsing than in progressive multiple sclerosis.
    Hamamcioglu K, Reder AT.
    Mult Scler; 2007 May; 13(4):459-70. PubMed ID: 17463069
    [Abstract] [Full Text] [Related]

  • 6. Cortical demyelination and diffuse white matter injury in multiple sclerosis.
    Kutzelnigg A, Lucchinetti CF, Stadelmann C, Brück W, Rauschka H, Bergmann M, Schmidbauer M, Parisi JE, Lassmann H.
    Brain; 2005 Nov; 128(Pt 11):2705-12. PubMed ID: 16230320
    [Abstract] [Full Text] [Related]

  • 7. Antibody-secreting cells in the central nervous system in an animal model of MS: Phenotype, association with disability, and in vitro production of antibody.
    Pachner AR, Brady J, Narayan K.
    J Neuroimmunol; 2007 Oct; 190(1-2):112-20. PubMed ID: 17919740
    [Abstract] [Full Text] [Related]

  • 8. [Multiple sclerosis: disease entity, subtypes and variants, and diagnostic criteria].
    Saida T.
    Nihon Rinsho; 2003 Aug; 61(8):1285-92. PubMed ID: 12962013
    [Abstract] [Full Text] [Related]

  • 9. Serum autoantibodies to cell surface determinants in multiple sclerosis: a flow cytometric study.
    Lily O, Palace J, Vincent A.
    Brain; 2004 Feb; 127(Pt 2):269-79. PubMed ID: 14662514
    [Abstract] [Full Text] [Related]

  • 10. Relationship of immunologic abnormalities and disease stage in multiple sclerosis: implications for therapy.
    Vaknin-Dembinsky A, Weiner HL.
    J Neurol Sci; 2007 Aug 15; 259(1-2):90-4. PubMed ID: 17521671
    [Abstract] [Full Text] [Related]

  • 11. Normal plasma antithrombin activity in patients with relapsing-remitting and secondary progressive multiple sclerosis.
    Campos-de-Magalhães M, de Almeida AJ, Papaiz-Alvarenga RM, Gadelha T, Morais-de-Sá CA, Alves-Leon SV.
    Clin Neurol Neurosurg; 2009 Jun 15; 111(5):407-11. PubMed ID: 19168277
    [Abstract] [Full Text] [Related]

  • 12. [Pathology and definition of multiple sclerosis].
    Dutta R, Trapp BD.
    Rev Prat; 2006 Jun 30; 56(12):1293-8. PubMed ID: 16948216
    [Abstract] [Full Text] [Related]

  • 13. The immunology of multiple sclerosis: disease mechanisms and therapeutic targets.
    Holmøy T.
    Minerva Med; 2008 Apr 30; 99(2):119-40. PubMed ID: 18431322
    [Abstract] [Full Text] [Related]

  • 14. ADC measurements in various patterns of multiple sclerosis lesions.
    Phuttharak W, Galassi W, Laopaiboon V, Laopaiboon M, Hesselink JR.
    J Med Assoc Thai; 2006 Feb 30; 89(2):196-204. PubMed ID: 16579006
    [Abstract] [Full Text] [Related]

  • 15. Compartmentalization of inflammation in the CNS: a major mechanism driving progressive multiple sclerosis.
    Meinl E, Krumbholz M, Derfuss T, Junker A, Hohlfeld R.
    J Neurol Sci; 2008 Nov 15; 274(1-2):42-4. PubMed ID: 18715571
    [Abstract] [Full Text] [Related]

  • 16. [Therapy of multiple sclerosis].
    Simó M.
    Neuropsychopharmacol Hung; 2009 Mar 15; 11(1):23-6. PubMed ID: 19731815
    [Abstract] [Full Text] [Related]

  • 17. Clinical stabilization and effective B-lymphocyte depletion in the cerebrospinal fluid and peripheral blood of a patient with fulminant relapsing-remitting multiple sclerosis.
    Stüve O, Cepok S, Elias B, Saleh A, Hartung HP, Hemmer B, Kieseier BC.
    Arch Neurol; 2005 Oct 15; 62(10):1620-3. PubMed ID: 16216948
    [Abstract] [Full Text] [Related]

  • 18. The natural history of multiple sclerosis: a geographically based study 9: observations on the progressive phase of the disease.
    Kremenchutzky M, Rice GP, Baskerville J, Wingerchuk DM, Ebers GC.
    Brain; 2006 Mar 15; 129(Pt 3):584-94. PubMed ID: 16401620
    [Abstract] [Full Text] [Related]

  • 19. Increased circulating antiganglioside antibodies in primary and secondary progressive multiple sclerosis.
    Sadatipour BT, Greer JM, Pender MP.
    Ann Neurol; 1998 Dec 15; 44(6):980-3. PubMed ID: 9851447
    [Abstract] [Full Text] [Related]

  • 20. Progressive multiple sclerosis cerebrospinal fluid induces inflammatory demyelination, axonal loss, and astrogliosis in mice.
    Cristofanilli M, Rosenthal H, Cymring B, Gratch D, Pagano B, Xie B, Sadiq SA.
    Exp Neurol; 2014 Nov 15; 261():620-32. PubMed ID: 25111532
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.